Ceftazidime, A New Cephalosporin in the Treatment of Complicated Urinary Tract Infections: A Comparative Study with Tobramycin

Publisher Website
Google Scholar
Abstract
In an open prospective randomized study, the safety and efficacy of ceftazidime were compared to those of tobramycin. Patients (51) were treated with ceftazidime (0.5 g i.m. every 12 h) or tobramycin (1 mg/kg i.m. every 8 h) for 7-10 days. Four patients were excluded from each treatment group, leaving 22 patients in the ceftazidime group and 21 in the tobramycin group. The groups were comparable in age, weight, underlying disorders of the urinary tract and distribution of bacteria. Cure was defined as sterile urine 7-10 days after treatment. The cure rate for ceftazidime was 73% and for tobramycin, 62% (0.6 < P < 0.7, .CHI.2 test with Yates correction). Both drugs were well tolerated; serum glutamic oxaloacetic transaminase rose in the tobramycin group. No patients had nephrotoxic reactions. Thus, ceftazidime is a safe and efficient treatment of complicated urinary tract infections.